A latest research report by IMARC group the titled is that “Pneumococcal Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, the global pneumococcal vaccine market grew at a CAGR of around 5% during 2015 & 2020. Pneumococcal infections are caused by Streptococcus pneumoniae or pneumococcus bacteria, which can cause severe lung infection (pneumonia), blood infection (bacteremia), and infection in the lining of the brain and spinal cord (meningitis). Children in the age group of 2-5 years and geriatric individuals are the most at-risk population for pneumococcal infections. The pneumococcal vaccine market share stimulates the immune system and prevents the spread of infection, thereby eliminating the need for hospitalization and reducing the fatality rate.
The rising parental concerns towards the high prevalence of pneumococcal infection in infants are propelling the demand for pneumococcal vaccines. Furthermore, the growing geriatric population who are more prone to chronic respiratory diseases is also augmenting the market growth. Additionally, the increasing consumption of cigarettes, snugs, cigars, hookah, etc., has further led to the rising incidences of severe lung diseases, thereby driving the global market. Additionally, the emergence of the Pneumococcal Conjugate Vaccine (PCV) for immunizing infants will continue to bolster the market growth in the coming years.
Get a sample copy of this Report: https://www.imarcgroup.com/pneumococcal-vaccine-market/requestsample
Report Coverage:
Historical, Current and Future Market Trends
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global pneumococcal vaccine market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, vaccine type, product type, distribution channel and end user.
Market Breakup by Vaccine Type:
- Pneumococcal Conjugate Vaccine
- Pneumococcal Polysaccharide Vaccine
Market Breakup by Product Type:
- Prevnar 13
- Synflorix
- Pneumovax 23
Market Breakup by Distribution Channel:
- Distribution Partner Companies
- Non-Governmental Organizations (NGO)
- Government Authorities
Market Breakup by End User:
- Pediatrics
- Adults
Market Breakup by Region:
- North America
- Asia-Pacific
- Europe
- Latin America
- Middle East and Africa
View Full Report with TOC & List of Figure: https://bit.ly/3baj1KU
Competitive Landscape with key players:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Astellas Pharma Inc., GlaxoSmithKline Plc., Merck & Co. Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt Ltd and Walvax Biotechnology Co. Ltd.
Note: As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Website: https://www.imarcgroup.com/
Email: [email protected]
USA: +1-631-791-1145
Follow us on twitter: @imarcglobal
